CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Q3 2026 Update: Tecan reports acceleration of sales growth in Q3 and raises full-year 2026 outlook

By GlobeNewswire

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules

Q3 2026 Update: Tecan reports acceleration of sales growth in Q3 and raises full-year 2026 outlook

Männedorf, Switzerland, November 5, 2026 – The Tecan Group (SIX Swiss Exchange: TECN) today provided an update on its performance for the third quarter of 2026, reporting an acceleration of sales growth to 6.9% in local currencies. Order entry grew by 3.1% in local currencies, despite a high comparison base from the prior-year period. In light of the strong performance year-to-date, Tecan is raising its outlook for both sales and adjusted EBITDA margin for the full year 2026.

At the segment level, sales in the Life Sciences Business grew by 5.6% in local currencies, driven by strong growth in the Biopharma customer segment. Notably, liquid handling instrument revenues increased significantly, with continued solid growth in recurring revenues from services, consumables and reagents.

Sales in the Partnering Business segment increased by 7.8% in local currencies, driven by substantial growth in in-vitro diagnostics systems within the Synergence product line and robust performance in Paramit CDMO manufacturing services, supported by a broad base of customers.

The “Rewired” transformation program, focused on portfolio discipline, commercial and operational excellence, is progressing according to plan.

2026 guidance increased and medium-term outlook confirmed
Based on the strong performance year-to-date, Tecan is raising its outlook for both sales and adjusted EBITDA margin for the full year 2026.

Full-year 2026 guidance (increased)PreviousUpdated
Sales, local currenciesLow single-digit growthLow to mid single-digit growth
Adjusted EBITDA margin115.5% to 16.5% of sales16.5% to 16.8% of sales

In the second half of 2026, Tecan received tariff refunds of CHF 6 million related to tariffs paid under the International Emergency Economic Powers Act. They will be included in reported earnings metrics such as EBIT, EBITDA, net earnings, and EPS. However, as these refunds are exceptional in nature, these refunds will not be reflected in adjusted earnings metrics. As a result, the refunds will not contribute to the adjusted EBITDA margin guidance.

The company also reiterates its medium-term outlook, as presented at the Capital Markets Update on March 16, 2026.

Full-year 2028 outlook (confirmed)
Sales1CHF 1 billion
Adjusted EBITDA margin120% of sales

1 Any changes to tariff rates may impact the outlook. Profitability expectations for 2026 and for the medium-term sales and adjusted EBITDA margin outlook are based on an average exchange rate forecast of one euro equaling CHF 0.92 and one US dollar equaling CHF 0.80.
About Tecan

Tecan (www.tecan.com) improves people’s lives and health by empowering customers to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has more than 3,000 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. In 2025, Tecan generated sales of CHF 883 million (USD 1,063 million; EUR 939 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).

For further information:

Tecan Group
Martin Brändle
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com

Attachment


Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.